CoQ10 (Ubiquinone)
What it is
Coenzyme Q10 (CoQ10) is a fat-soluble compound found in virtually every cell in the body, with the highest concentrations in tissues with high energy demands, the heart, liver, kidneys, and skeletal muscle. It plays a central role in mitochondrial ATP production and functions as a lipid-soluble antioxidant in cell membranes. The body synthesises CoQ10 endogenously, but synthesis declines with age and is reduced by certain medications, particularly statins.
CoQ10 exists in two interconvertible forms: ubiquinone (the oxidised form) and ubiquinol (the reduced form). Ubiquinone is the standard studied form in clinical trials and has the largest evidence base. Ubiquinol has not demonstrated superior clinical outcomes compared to ubiquinone in adequately powered head-to-head trials for the key outcomes reviewed here.
What the evidence shows
Heart failure is the best-evidenced application. The Q-SYMBIO trial found that CoQ10 supplementation at 300mg/day as an adjunct to standard heart failure therapy reduced major adverse cardiovascular events and cardiovascular mortality over two years. This is an important finding, but it has not been replicated in a large contemporary trial using current standard heart failure therapy, and the overall evidence base relies heavily on this single pivotal trial. Improvements in ejection fraction and exercise tolerance seen in meta-analyses are meaningful intermediate endpoints, but improvements in these measures do not necessarily translate into mortality benefit and should not be read as equivalent to event-level evidence from multiple large trials.
Statin-associated muscle symptoms (SAMS) represent the most common reason for CoQ10 supplementation. Statins reduce CoQ10 synthesis alongside cholesterol, and muscle CoQ10 concentrations are lower in statin users. Clinical trials show mixed results, some show small to modest reductions in pain scores; others show no benefit over placebo. The placebo response in SAMS trials is substantial, no clear responder phenotype has been identified, and effect sizes where present are small to modest with high variability.
Fertility in women is an emerging application. Small trials in women undergoing IVF show modest improvements in ovarian response metrics and embryo quality. The mechanistic rationale, declining mitochondrial function in ageing oocytes, is stronger than the current clinical outcome evidence. Live birth rates, which are the clinically important endpoint, remain insufficiently established.
What the evidence does not show
General energy enhancement, cognitive improvement, and anti-ageing effects in healthy adults without specific indication are not supported, trials are generally null in these populations. No evidence shows that restoring CoQ10 levels reverses age-related functional decline in healthy older adults.
Ubiquinol has not demonstrated superior clinical outcomes to ubiquinone in adequately powered comparative trials.
Form and dose considerations
Ubiquinone is the standard studied form. Typical evidence-based doses range from 100-300mg/day; the Q-SYMBIO trial used 300mg/day. CoQ10 is fat-soluble and absorption is significantly improved when taken with a meal containing fat. Soft-gel formulations generally have better bioavailability than powder-filled capsules. Circulating CoQ10 levels may not reliably reflect tissue bioavailability, limiting the utility of plasma CoQ10 as a monitoring tool.
Who the evidence applies to
The evidence is strongest for individuals with heart failure as an adjunct to standard treatment, those taking statins who experience muscle symptoms, and older women with fertility concerns undergoing IVF. Healthy adults without these specific indications are unlikely to benefit meaningfully based on current evidence.
Safety and contraindications
CoQ10 is well-tolerated across a wide dose range. A modest interaction with warfarin has been reported, individuals on anticoagulants should monitor INR when starting supplementation. GI effects including nausea and loose stools occur at higher doses and are reduced by splitting the daily dose. A modest blood pressure lowering effect has been reported in some trials; individuals on antihypertensive medication should be aware of this.
What can reasonably be concluded
CoQ10 has meaningful evidence in specific populations: heart failure as an adjunct to standard therapy, statin-associated muscle symptoms, and fertility in older women or those with diminished ovarian reserve undergoing IVF. In each case the evidence base has important limitations, single trial dominance in heart failure, mixed results and high placebo response in SAMS, surrogate endpoints and absent live birth data in fertility, that should temper confidence.
For healthy adults without specific indication, evidence for general energy, cognitive, or anti-ageing benefit is insufficient.
Where evidence is limited or outcomes are uncertain, conclusions should be treated as provisional and subject to revision as the evidence base develops.